IMMUNOCORE LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Deloitte LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Given the current cash position and the assessment performed, the Board believes that the Company will have sufficient funds to continue to meet its liabilities as they fall due for a period of one year from the date of signing these financial statements.”

Group structure

1. IMMUNOCORE LIMITED · parent
   1. Immunocore LLC 100% · United States · Clinical Monitoring Services
   2. Immunocore Commercial LLC 100% · United States · Distribution services
   3. Immunocore Nominees Limited 100% · United Kingdom · Employee Benefit Trust
   4. Immunocore Ireland Ltd 100% · Ireland · Distribution services
   5. Immunocore GmbH 100% · Switzerland · Distribution services

Significant events

• “On 8 November 2024, the Company repaid in full, the loan outstanding under the Pharmakon Loan Agreement, under which the Company had borrowed $50 million. The aggregate cash payment to terminate the Pharmakon Loan Agreement was £40.1 million ($52.1 million) and consisted of £38.6 million ($50.0 million) for principal, £0.4 million ($0.5 million) accrued interest and £1.1 million ($1.6 million) attributable to a prepayment premium and other expenses payable by the Company in relation to the Agreement.”
• “In June 2025, the Group initiated a voluntary recall of KIMMTRAK (tebentafusp) bulk drug product Batch 3D009A relating to an unexpected decrease in an in vitro potency assay for this Batch, identified during routine stability testing.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +15.4%

  £239,160,000 → £276,075,000

• Cash

  +3.9%

  £299,450,000 → £311,016,000

• Net assets

  +130.1%

  £39,334,000 → £90,517,000

• Employees

  +4.2%

  335 → 349

• Operating profit

  -39.5%

  £14,883,000 → £9,000,000

• Profit before tax

  +86.4%

  £15,994,000 → £29,819,000

• Wages

  +11.1%

  £24,484,000 → £27,205,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers